NCT04985357 2024-11-25
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Withdrawn
Travera Inc
Université de Montréal
Case Comprehensive Cancer Center
CSA Medical, Inc.
Case Comprehensive Cancer Center